Literature DB >> 27279458

Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways.

Mingjie Lu1, Chen Wang2, Jian Wang1.   

Abstract

Colorectal cancer (CRC) is one of the most common malignancies worldwide and a leading cause of cancer death. Despite decades of intensive investigations, effective interventional options are still limited and patient prognosis remains poor. Tanshinone I, an active compound from traditional Chinese herbal medicine Salvia miltiorrhiza Bunge, has been shown to inhibit cell growth of leukemia, lung, and breast cancers. However, whether and how Tanshinone I exerts similar effects on CRC needs to be elucidated. Tanshinone I induced CRC cell apoptosis was characterized and the roles of Aurora A-p53 and survivin-mediated pathways were analyzed in different CRC cell lines. Tanshinone I markedly inhibited CRC cell growth and induced apoptosis in CRC cells with functional p53 protein. Interestingly, Tanshinone I did not exert as much inhibitory effect on normal colon epithelial cells or CRC cells with mutant p53, indicating relative selectivity toward colorectal cancer cells with full presence of p53. In tse cells with wild-type p53, data showed that Tanshinone I mediated Aurora A inhibition results in p53 upregulation, which is required for cell apoptosis. In CRC cells with mutant p53 protein (not able to localize to the nucleus), however, Aurora A knockdown failed to induce CRC cell apoptosis. Instead, data showed that protein level of survivin decreased following Tanshinone I treatment. These observations were further substantiated by the pivotal role of survivin in Tanshinone I mediated apoptosis in CRC cells with p53 mutant. Tanshinone I, a novel natural compound, exerts significant inhibitory effect on CRC cell growth via a mechanism involving either Aurora A-p53 axis or survivin-involving mechanism depending on different intrinsic characteristics of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27279458     DOI: 10.3892/ijo.2016.3565

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells.

Authors:  Xinglei Qin; Min Lu; Yajun Zhou; Gang Li; Zhaoyang Liu
Journal:  Cell Cycle       Date:  2019-04-14       Impact factor: 4.534

2.  Tanshinone I restrains osteosarcoma progression by regulating circ_0000376/miR-432-5p/BCL2 axis.

Authors:  Baoguo Ye; Kong Qiao; Qiheng Zhao; Zhigang Jiang; Ningning Hu; Fei Wang
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

Review 3.  Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms.

Authors:  Huan Zhao; Bing Han; Xuan Li; Chengtao Sun; Yufei Zhai; Man Li; Mi Jiang; Weiping Zhang; Yi Liang; Guoyin Kai
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

4.  miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells.

Authors:  Rong Yang; Minghui Liu; Hongwei Liang; Suhan Guo; Xu Guo; Min Yuan; Huibo Lian; Xiang Yan; Shiwei Zhang; Xi Chen; Feng Fang; Hongqian Guo; Chenyu Zhang
Journal:  Mol Cancer       Date:  2016-12-15       Impact factor: 27.401

5.  Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway.

Authors:  Ching-Yuan Wu; Yao-Hsu Yang; Yin-Yin Lin; Feng-Che Kuan; Yu-Shin Lin; Wei-Yu Lin; Ming-Yen Tsai; Jia-Jing Yang; Yu-Ching Cheng; Li-Hsin Shu; Ming-Chu Lu; Yun-Ju Chen; Kuan-Der Lee; Hong-Yo Kang
Journal:  Oncotarget       Date:  2017-06-20

6.  Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1.

Authors:  Jiao Yu; Xiaoxia Wang; Yuhua Li; Bin Tang
Journal:  Oncol Rep       Date:  2017-01-30       Impact factor: 3.906

Review 7.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.

Authors:  Ruijuan Du; Chuntian Huang; Kangdong Liu; Xiang Li; Zigang Dong
Journal:  Mol Cancer       Date:  2021-01-15       Impact factor: 27.401

8.  Tanshinone Suppresses Arecoline-Induced Epithelial-Mesenchymal Transition in Oral Submucous Fibrosis by Epigenetically Reactivating the p53 Pathway.

Authors:  Lian Zheng; Zhen-Jie Guan; Wen-Ting Pan; Tian-Feng Du; Yu-Jia Zhai; Jia Guo
Journal:  Oncol Res       Date:  2017-05-21       Impact factor: 5.574

9.  Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.

Authors:  Jin Zhou; Yuan-Yuan Jiang; Huan Chen; Yi-Chao Wu; Li Zhang
Journal:  Cell Prolif       Date:  2019-12-09       Impact factor: 6.831

10.  Evaluation of the anti-inflammatory effects of synthesised tanshinone I and isotanshinone I analogues in zebrafish.

Authors:  Matthew J Foulkes; Faith H Tolliday; Katherine M Henry; Stephen A Renshaw; Simon Jones
Journal:  PLoS One       Date:  2020-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.